Biotech Values

[rfj1862]

Keep in mind that MRKR management probably had little/nothing to do with writing the abstract, other than maybe getting a courtesy review from the faculty who submitted it, and maybe not even that. Academics like to preserve their "independence" even if it means they are shooting themselves in the foot.

Overall this is a complete non-event--the abstract had no clinical data in it, it was just a design, apparently. So it wasn't rejected on the basis of poor clinical data (nor would ASCO reject an abstract because the data showed a bad result).

The only disappointment is that we do not get to hear about the pancreatic data now.